Paul Cook - Concepedia

Author

Paul Cook

Also Known As

Brian G. Southwell, Cook, P P, Cook, Paul, Cook, Paul P., P Cook, P P Cook, P. Cook, P. P. Cook, P.P. Cook, PAUL P. COOK

122

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

East Carolina University Vidant Medical Center Duke Medical Center University of Nebraska Medical Center Merck & Co., Inc., Rahway, NJ, USA (United States)

About

Paul Cook is an author at East Carolina University specializing in medicine, antimicrobial resistance, and infection control.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	22	1.2K
2	Health Sciences	4	4	156
3	Natural Sciences	4	4	344
4	Engineering	1	1	15
5	Humanities	1	1	11

Paul Cook

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by <i>Staphylococcus aureus</i> Vance G. Fowler, Helen W. Boucher, G. Ralph Corey, New England Journal of Medicine	2006	1.5K
Effect of phorbol esters on protein kinase C-zeta. D. Kirk Ways, Paul Cook, Carol Brenner Webster, Journal of Biological Chemistry Molecular PharmacologySignal TransductionCell RegulationBiochemistryTpa-dependent Kinase Activity	1992	278
MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. D. Kirk Ways, Cindy Kukoly, James DeVente, Journal of Clinical Investigation	1995	267
The impact of penicillin skin testing on clinical practice and antimicrobial stewardship Ramzy H. Rimawi, Paul Cook, Michael D. Gooch, Journal of Hospital Medicine	2013	141
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial Jean‐Michel Molina, Kathleen Squires, Paul E. Sax, The Lancet HIV Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyNon-inferiority Trial	2018	140
Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent Tuberculosis L McNeill, Myra Allen, Carlos A. Estrada, CHEST Journal Medicinal ChemistryPulmonary TuberculosisLatent TuberculosisMedicineTuberculosis Prevention	2003	135
Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram Paul Cook Journal of Antimicrobial Chemotherapy	2004	122
Impact of Regular Collaboration Between Infectious Diseases and Critical Care Practitioners on Antimicrobial Utilization and Patient Outcome* Ramzy H. Rimawi, Mark A. Mazer, Dawd Siraj, Critical Care Medicine	2013	114
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial Jean‐Michel Molina, Kathleen Squires, Paul E. Sax, The Lancet HIV Treatment And PreventionAntiretroviral-naive AdultsClinical TrialsAntiviral Drug DevelopmentAntiviral Therapy	2019	92
Near-Drowning Complicated by Brain Abscess due to Petriellidium boydii John F. Fisher, Smith Shadomy, J. R. Teabeaut, Archives of Neurology Parasitic DiseaseAntifungal AgentHealth SciencesAntiparasitic AgentAntifungal Agents	1982	74

Page 1